Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pediatric oncology

What Are the Main Types of Osteosarcoma in Children?

At a Glance

Osteosarcoma subtypes describe the tumor's cell pattern and whether it starts inside the bone or on its surface. Most conventional high-grade types receive chemotherapy and surgery; grade, stage, clear surgical edges, and treatment response guide care and outlook.

Yes, there are several different types of osteosarcoma. When you read a pathology report, you will likely see two main ways the tumor is classified: by its histologic subtype (what the cells look like under a microscope and what kind of material they produce) and by its location relative to the bone (whether it started inside the bone or on the surface) [1][2].

It is completely normal to feel overwhelmed by the complex medical terms on these reports. While these specific classifications provide important details, the subtype alone does not tell the whole story. A child’s treatment plan and overall outlook also depend heavily on the tumor’s stage (whether it has spread, such as to the lungs), its grade (how aggressive the cells look), and whether the tumor can be completely removed with surgery [3][4].

Histologic Subtypes: What the Cells Look Like

Most childhood osteosarcomas are “conventional high-grade” tumors [1]. In pathology, high-grade does not just mean the cells divide quickly; it means the cells look very abnormal, are disorganized, and show high microscopic activity, indicating a more aggressive tumor [5][6].

Within this conventional group, pathologists categorize the tumor based on the type of matrix (connective material) the cancer cells are producing. The three most common conventional subtypes are:

  • Osteoblastic: The cancer cells primarily produce large amounts of abnormal bone material, called osteoid [1].
  • Chondroblastic: The cancer cells produce a cartilage-like material [1].
  • Fibroblastic: The cancer cells look more like spindle-shaped connective tissue cells [1].

What this means for treatment: Seeing “osteoblastic” or “chondroblastic” on a report can be intimidating, but these three conventional high-grade subtypes generally share the same treatment backbone: systemic chemotherapy (drugs that travel throughout the body) given before and after surgery [7][2]. The specific subtype does not significantly change the overall prognosis [8]. Instead, care teams look closely at how well the tumor responds to the initial chemotherapy. This is measured after surgery by the pathologist, who checks the removed tumor tissue to see how much of it has died (a process called necrosis) [9][3].

There are also a few less common high-grade subtypes:

  • Telangiectatic osteosarcoma: This type features blood-filled cysts and can sometimes be mistaken for a benign bone cyst on an X-ray [10]. Despite its unique appearance, it is generally managed with the same chemotherapy and surgery approach as other conventional high-grade tumors [11].
  • Small-cell osteosarcoma: The cells in this rare subtype look very similar to Ewing sarcoma. Pathologists often need to run special molecular or genetic tests on the tumor tissue itself (these are not tests for an inherited genetic condition) to confirm the diagnosis and ensure the correct treatment plan is used [12].

(Note: This guide focuses on the most common pediatric subtypes. If you see a term not listed here, ask your child’s oncologist to explain it.)

Intramedullary vs. Surface Lesions: Where the Tumor Starts

Osteosarcoma is also classified by where it physically begins growing in the bone. This classification helps doctors decide the best surgical approach and whether chemotherapy is necessary.

Intramedullary (Central) Osteosarcoma

These tumors start inside the bone marrow cavity (the hollow center of the bone).

  • Conventional high-grade osteosarcoma is intramedullary and is the most common type [2]. Because it is aggressive, standard treatment involves systemic chemotherapy and surgery [3].
  • Low-grade central osteosarcoma is a much less common intramedullary type. Because it is low-grade, it is usually treated with wide surgical removal (taking out the tumor along with a healthy border of tissue) [13]. Chemotherapy is generally not needed unless the pathologist finds high-grade areas within the tumor.

Surface Osteosarcomas

These tumors grow on the outside surface (cortex) of the bone. They account for a smaller percentage of cases and are categorized by their grade:

  • Parosteal osteosarcoma: This is a low-grade, slow-growing tumor on the bone’s surface. It is often treated with surgery alone, provided the surgeon can achieve clear margins (meaning no cancer cells are seen at the outer edge of the removed tissue) [14][13]. Chemotherapy is usually considered only if the tumor has “dedifferentiated” (developed high-grade, aggressive areas) or spread [15].
  • Periosteal osteosarcoma: This is considered an intermediate-grade surface tumor. It requires surgery, but the decision to add chemotherapy is highly individualized based on the tumor’s specifics [16][14].
  • High-grade surface osteosarcoma: This tumor grows on the surface but behaves aggressively, just like a conventional intramedullary tumor. Therefore, it is generally managed using the same approach: both chemotherapy and surgery [17][14].

Common questions in this guide

What are the main histologic types of osteosarcoma?
The common conventional high-grade types are osteoblastic, chondroblastic, and fibroblastic osteosarcoma. Osteoblastic tumors make abnormal bone material, chondroblastic tumors make cartilage-like material, and fibroblastic tumors have spindle-shaped cells. Telangiectatic and small-cell osteosarcoma are less common types.
What does the subtype on an osteosarcoma pathology report mean for treatment?
The subtype describes how the tumor cells look and what material they produce, but it usually does not determine treatment by itself. Most conventional high-grade subtypes are treated with chemotherapy before and after surgery. Stage, grade, whether the tumor can be completely removed, and its response to chemotherapy also guide the plan.
What is the difference between intramedullary and surface osteosarcoma?
Intramedullary osteosarcoma starts inside the bone's marrow cavity, while surface osteosarcoma grows on the outer surface of the bone. This location helps doctors plan surgery and decide whether chemotherapy is needed. Surface tumors include parosteal, periosteal, and high-grade surface osteosarcoma.
Are parosteal and low-grade central osteosarcomas treated with chemotherapy?
Often, these low-grade tumors are treated primarily with wide surgical removal. Chemotherapy is usually not needed for low-grade central osteosarcoma or parosteal osteosarcoma unless high-grade areas, dedifferentiation, or spread are present. The treatment decision depends on the tumor's full pathology and imaging.
How is chemotherapy response measured in osteosarcoma?
After surgery, the pathologist examines the removed tumor to estimate how much has died, called tumor necrosis. This measurement shows how the tumor responded to the chemotherapy given before surgery. It is one factor doctors use when assessing the child's care and outlook.
Why might small-cell osteosarcoma need molecular testing?
Small-cell osteosarcoma can look like Ewing sarcoma under the microscope. Tests performed on the tumor tissue can help confirm the diagnosis and ensure the treatment is appropriate. These are tumor tests, not tests for an inherited genetic condition.
Why are clear margins important in osteosarcoma surgery?
A clear margin means no cancer cells are seen at the outer edge of the tissue removed by the surgeon. Achieving clear margins helps show that the tumor was removed with a surrounding border of healthy tissue, and it is an important surgical goal. The surgeon and pathology team determine whether margins are clear.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific histologic subtype, grade, and stage of my child's tumor, and what do those mean for the treatment plan?
  2. 2.Has the biopsy been reviewed by a pathologist who specializes in pediatric bone tumors or sarcomas?
  3. 3.Were any special molecular tests done on the tumor tissue to confirm the diagnosis or rule out other cancers?
  4. 4.Is the tumor located inside the bone (intramedullary) or on the surface, and how does that influence our options?
  5. 5.After surgery, how will the pathologist measure the tumor's necrosis (response to chemotherapy)?
  6. 6.Are we aiming for a limb-sparing surgery, and what does it mean for the surgeon to achieve 'clear margins'?
  7. 7.If the tumor is a surface type like parosteal, does it show any signs of high-grade areas (dedifferentiation) that might require chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Update on Conventional Osteosarcoma.

    Teixeira LEM, Guedes A, Nakagawa SA, et al.

    Revista brasileira de ortopedia 2024; (59(6)):e815-e820 doi:10.1055/s-0043-1771483.

    PMID: 39711636
  2. 2

    The current status of MRI in the pre-operative assessment of intramedullary conventional appendicular osteosarcoma.

    Saifuddin A, Sharif B, Gerrand C, Whelan J

    Skeletal radiology 2019; (48(4)):503-516 doi:10.1007/s00256-018-3079-1.

    PMID: 30288560
  3. 3

    The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents.

    Zarghooni K, Bratke G, Landgraf P, et al.

    Deutsches Arzteblatt international 2023; (120(24)):405-412.

    PMID: 37097079
  4. 4

    Preoperative surgical risk stratification in osteosarcoma based on the proximity to the major vessels.

    Fujiwara T, Medellin MR, Sambri A, et al.

    The bone & joint journal 2019; (101-B(8)):1024-1031 doi:10.1302/0301-620X.101B8.BJJ-2018-0963.R1.

    PMID: 31362545
  5. 5

    Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.

    Chow LT

    Virchows Archiv : an international journal of pathology 2016; (468(6)):741-55 doi:10.1007/s00428-016-1926-9.

    PMID: 27003154
  6. 6

    Giant cell-rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients.

    Karczewski D, Gonzalez MR, Bedi A, et al.

    Journal of surgical oncology 2023; (128(5)):877-890 doi:10.1002/jso.27368.

    PMID: 37292033
  7. 7

    Advances in the management of osteosarcoma.

    Bielack SS, Hecker-Nolting S, Blattmann C, Kager L

    F1000Research 2016; (5()):2767 doi:10.12688/f1000research.9465.1.

    PMID: 27990273
  8. 8

    Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

    Vasquez L, Tarrillo F, Oscanoa M, et al.

    Frontiers in oncology 2016; (6()):22 doi:10.3389/fonc.2016.00022.

    PMID: 26904501
  9. 9

    Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma.

    Patel N, Werenski JO, Gonzalez MR, et al.

    Surgical oncology 2024; (57()):102155 doi:10.1016/j.suronc.2024.102155.

    PMID: 39423470
  10. 10

    A Primary Telangiectatic Mandibular Osteosarcoma With Germ-Line Malignancy-Associated DNA Damage Repair Gene Polymorphisms: A Case Report.

    Tahir M, Wei EX, Madelaire C, et al.

    Case reports in oncological medicine 2024; (2024()):2418888 doi:10.1155/2024/2418888.

    PMID: 38962713
  11. 11

    Prognostic analysis of telangiectatic osteosarcoma of the extremities.

    Zhong W, Luo W, Lin Z, et al.

    Frontiers in oncology 2022; (12()):1105054 doi:10.3389/fonc.2022.1105054.

    PMID: 36815074
  12. 12

    Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone: retrospective clinical, radiological, pathological, and (epi)genetic comparison with clinical implications.

    Hiemcke-Jiwa LS, Sumathi VP, Baumhoer D, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(3)):451-463 doi:10.1007/s00428-024-03747-2.

    PMID: 38332052
  13. 13

    Low-grade central osteosarcoma in proximal humerus: a rare entity.

    Tang F, Min L, Zhou Y, et al.

    OncoTargets and therapy 2017; (10()):5165-5172 doi:10.2147/OTT.S142818.

    PMID: 29123414
  14. 14

    Surface osteosarcoma: Clinical features and therapeutic implications.

    Nouri H, Ben Maitigue M, Abid L, et al.

    Journal of bone oncology 2015; (4(4)):115-23 doi:10.1016/j.jbo.2015.07.002.

    PMID: 26730360
  15. 15

    The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma.

    Laitinen M, Parry M, Albergo JI, et al.

    The bone & joint journal 2015; (97-B(12)):1698-703 doi:10.1302/0301-620X.97B12.35749.

    PMID: 26637687
  16. 16

    Periosteal Osteosarcoma: A Single-Institutional Study of Factors Related to Oncologic Outcomes.

    Chan CM, Lindsay AD, Spiguel ARV, et al.

    Sarcoma 2018; (2018()):8631237 doi:10.1155/2018/8631237.

    PMID: 30363676
  17. 17

    High-Grade Surface Osteosarcoma: Clinical Features and Oncologic Outcome.

    Deng Z, Huang Z, Ding Y, et al.

    Journal of bone oncology 2020; (23()):100288 doi:10.1016/j.jbo.2020.100288.

    PMID: 32953434

This page is for informational purposes only and does not constitute medical advice. Your child's oncology and pathology team should interpret the report and recommend treatment for your child.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.